Levosimendan for Low Cardiac Output: A Pediatric Experience

This was a retrospective observational study in a pediatric intensive care unit, in which 19 patients received levosimendan. There were no adverse events attributable to levosimendan and no instances where the clinical condition worsened after administration. Arterial lactate levels decreased signif...

Full description

Saved in:
Bibliographic Details
Published in:Journal of intensive care medicine 2006-05, Vol.21 (3), p.183-187
Main Authors: Egan, Jonathan R., Clarke, Andrew J. B., Williams, Stephen, Cole, Andrew D., Ayer, Julian, Jacobe, Stephen, Chard, Richard B., Winlaw, David S.
Format: Article
Language:English
Subjects:
Adolescent
Cardiac Output, Low - drug therapy
Cardiac Output, Low - etiology
Cardiac patients
Cardiotonic Agents - administration & dosage
Cardiotonic Agents - pharmacology
Cardiotonic Agents - therapeutic use
Child
Child, Preschool
Complications and side effects
Congenital heart disease
Dietary supplements
Dosage and administration
Drug therapy
Drug-Related Side Effects and Adverse Reactions
Health aspects
Heart Defects, Congenital - complications
Heart Defects, Congenital - drug therapy
Hemodynamics - drug effects
Humans
Hydrazones - administration & dosage
Hydrazones - pharmacology
Hydrazones - therapeutic use
Infant
Infant, Newborn
Infusions, Intravenous
Management
Pediatric intensive care
Pyridazines - administration & dosage
Pyridazines - pharmacology
Pyridazines - therapeutic use
Retrospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This was a retrospective observational study in a pediatric intensive care unit, in which 19 patients received levosimendan. There were no adverse events attributable to levosimendan and no instances where the clinical condition worsened after administration. Arterial lactate levels decreased significantly following levosimendan administration during cardiopulmonary bypass for anticipated low cardiac output. In those with established low cardiac output, trends toward improved hemodynamics were seen, with heart rate reduction, an increase in mean blood pressure, a reduction in arterial lactate, and reduced conventional inotrope use. Levosimendan was safely used in a small number of pediatric patients with established low cardiac output state who demonstrated improved hemodynamics and tissue perfusion, with a tendency to reduced conventional inotrope usage, and this warrants its evaluation as an inotrope in the pediatric population.
ISSN:0885-0666
1525-1489
DOI:10.1177/0885066606287039